These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1142753)

  • 1. Prevention of experimental postoperative adhesions by ancrod defibrinogenation.
    Buckman RF; Bordos D; Bell WR; Cameron JL
    J Surg Res; 1975 Apr; 18(4):377-84. PubMed ID: 1142753
    [No Abstract]   [Full Text] [Related]  

  • 2. Adhesion prevention with ancrod released via a tissue-adherent hydrogel.
    Chowdhury SM; Hubbell JA
    J Surg Res; 1996 Feb; 61(1):58-64. PubMed ID: 8769943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of postoperative tendon adhesions by ancrod defibrinogenation.
    Buckman RF; Woods M; Bell WR; Buckman PD; Zuidema GD
    Surgery; 1977 Nov; 82(5):721-6. PubMed ID: 411190
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog.
    Daniel TM; Pizzo SV; Mckee PA
    Ann Surg; 1976 Aug; 184(2):223-8. PubMed ID: 952568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation studies during therapeutic application of arvin.
    Vinazzer H
    Thromb Res; 1976 Feb; 8(2):243-8. PubMed ID: 943132
    [No Abstract]   [Full Text] [Related]  

  • 6. Proceedings: Clinical improvement in peripheral circulation by controlled defibrinogenation.
    Dormandy JA; Goyle KB
    Br J Surg; 1976 Aug; 63(8):661-2. PubMed ID: 953495
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology.
    Forbes CD; Barbenell J; Prentice CR
    Haemostasis; 1976; 5(6):348-54. PubMed ID: 1017726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodilution combined with defibrinogenation.
    Böhme H; Everts B
    Bibl Haematol; 1981; (47):165-72. PubMed ID: 7039611
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of severe intermittent claudication by controlled defibrination.
    Dormandy JA; Goyle KB; Reid HL
    Lancet; 1977 Mar; 1(8012):625-6. PubMed ID: 66429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SDS polyacrylamide gel characterization of serum FDP produced in response to ancrod and streptokinase/plasminogen infusion in man.
    Lane DA; Robbins A; Rampling MW; Kakkar VV
    Br J Haematol; 1977 May; 36(1):137-48. PubMed ID: 871418
    [No Abstract]   [Full Text] [Related]  

  • 11. Functional outcome of discordant xenoislet grafts from a large animal donor after recipient defibrinogenation with Ancrod.
    Troppmann C; Zhang K; Gruessner AC; West M; Gruessner RW
    Transplant Proc; 1997 Jun; 29(4):2170-2. PubMed ID: 9193575
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous ancrod in prevention of deep vein thrombosis after hip replacement surgery.
    Belch JJ; Meek DR; Lowe GD; Campbell AF; Young AB; Forbes CD; Prentice CR
    Thromb Res; 1982 Jan 1-15; 25(1-2):23-31. PubMed ID: 7038977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arwin in peripheral arterial circulatory disorders: controlled multicentre trials.
    Wolf GK
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):387-92. PubMed ID: 786664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A report on the use of Arvin in patients with pre-gangrene of the lower limb.
    Humphreys WV; Walker A; Charlesworth D
    Br J Surg; 1977 Jan; 64(1):31-3. PubMed ID: 831951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aspects of defibrinogenation therapy].
    Klüken N
    Phlebologie; 1975; 28(1):39-41. PubMed ID: 1202532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo production of soluble complexes containing fibrinogen-fibrin related antigen during ancrod therapy.
    McKillop C; Edgar W; Forbes CD; Prentice CR
    Thromb Res; 1975 Sep; 7(3):361-72. PubMed ID: 1188838
    [No Abstract]   [Full Text] [Related]  

  • 17. Possible pathway for formation of fibrin degradation products during ancrod therapy.
    McKillop C; Edgar W; Forbes CD; Prentice CR
    Nature; 1975 Jun; 255(5510):638-40. PubMed ID: 1134556
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative effects of heparin, urokinase, and ancrod on intraglomerular coagulation induced in progressive Masugi nephritis.
    Dohi K; Fujioka M; Nakamoto Y
    Acta Pathol Jpn; 1982 Nov; 32(6):1047-52. PubMed ID: 6760667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to arvin following prolonged intravenous therapy.
    Sapru RP; Moza AK; Kumar M; Ganguly NK
    Thromb Res; 1975 Oct; 7(4):635-41. PubMed ID: 1198550
    [No Abstract]   [Full Text] [Related]  

  • 20. [Modified dosage scheme for the subcutaneous use of arvin in patients with chronic arterial occlusive diseases].
    Ehrly AM; Köhler HJ
    Vasa; 1976; 5(2):155-62. PubMed ID: 973426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.